Collplant Holdings ADR Aktie News

-- New North American logistics center will provide expanded distribution for CollPlant's rhCollagen and BioInks as well as enable logistical efficiencies -- REHOVOT, Israel , Oct. 27, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rh...

A head-to-head study by Israel's Technion found that CollPlant's rhCollagen-based bioink, Collink.3D ™, outperformed Matrigel®, a leading extracellular matrix, in supporting structured tissue formation. The findings suggest Collink.3D ™ could offer a consistent, tunable, and animal-free alternative for advanced tissue engineering and research applications.

The bioprinted skin model is designed to serve as an alternative to animal testing for preclinical research. According to a scientific article published in the Archives of Dermatological Research, the model developed by Mayo Clinic researchers combines CollPlant's plant-derived recombinant human collagen (rhCollagen) with distinct and essential human skin cell types.

CollPlant is now moving towards clinical trials and scaling and optimizing its manufacturing to ensure readiness for the upcoming clinical trials REHOVOT, Israel , Sept. 30, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing disruptive technologies and products based on its proprietary non-animal recombinant human collagen (rh...

REHOVOT, Israel , Sept. 15, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), or 'CollPlant', a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced the expansion of its European distribution network for Vergenix™ STR through the signing o...

REHOVOT, Israel , Sept. 2, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen), today announced its participation in the annual meeting of The International Society of Biofabrication: the International Conference on Biof...

REHOVOT, Israel , Aug. 25, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen), today announced that senior management will participate in the upcoming 27th Annual H.C. Wainwright Global Investment Conference on Monday,...

- Sales of rhCollagen and bioinks primed for augmentation following new U.S.-based commercial executive hire - - Raised $3.6 million in registered direct offering in second quarter -  REHOVOT, Israel , Aug. 20, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-deri...